Cliff Asness's XRAY Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 3.97 M shares of DENTSPLY SIRONA Inc. (XRAY) worth $45.12 M, representing 0.02% of the portfolio. First purchased in 2016-Q1, this long-term strategic position has been held for 41 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in XRAY, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2025, adding 6.97 M shares. Largest reduction occurred in Q4 2025, reducing 7.6 M shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's DENTSPLY SIRONA (XRAY) Holding Value Over Time
Track share changes against reported price movement
Quarterly DENTSPLY SIRONA (XRAY) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -932,913 | Reduce 19.05% | 3.97 M | $11.38 |
| Q4 2025 | -7.6 M | Reduce 60.82% | 4.9 M | $11.43 |
| Q3 2025 | -816,405 | Reduce 6.13% | 12.5 M | $12.64 |
| Q2 2025 | +6.97 M | Add 109.82% | 13.32 M | $15.88 |
| Q1 2025 | +3.45 M | Add 119.38% | 6.35 M | $14.72 |
| Q4 2024 | +2.05 M | Add 245.12% | 2.89 M | $18.80 |
| Q3 2024 | +456,061 | Add 119.33% | 838,256 | $26.86 |
| Q2 2024 | +207,704 | Add 119.03% | 382,195 | $24.91 |
| Q1 2024 | +36,818 | Add 26.74% | 174,491 | $32.93 |
| Q4 2023 | -48,411 | Reduce 26.02% | 137,673 | $35.57 |
| Q3 2023 | +67,372 | Add 56.75% | 186,084 | $34.16 |
| Q2 2023 | -16,555 | Reduce 12.24% | 118,712 | $39.76 |
| Q1 2023 | -496,691 | Reduce 78.60% | 135,267 | $39.05 |
| Q4 2022 | +99,404 | Add 18.67% | 631,958 | $31.84 |
| Q3 2022 | -403,525 | Reduce 43.11% | 532,554 | $28.35 |
| Q2 2022 | +388,388 | Add 70.91% | 936,079 | $35.50 |
| Q1 2022 | -25,940 | Reduce 4.52% | 547,691 | $49.11 |
| Q4 2021 | +191,533 | Add 50.13% | 573,631 | $55.79 |
| Q3 2021 | +47,156 | Add 14.08% | 382,098 | $58.05 |
| Q2 2021 | +103,945 | Add 45.00% | 334,942 | $62.82 |
| Q1 2021 | +33,999 | Add 17.26% | 230,997 | $63.81 |
| Q4 2020 | -190,728 | Reduce 49.19% | 196,998 | $51.22 |
| Q3 2020 | -69,939 | Reduce 15.28% | 387,726 | $43.19 |
| Q2 2020 | -23,190 | Reduce 4.82% | 457,665 | $43.77 |
| Q1 2020 | +22,589 | Add 4.93% | 480,855 | $38.79 |
| Q4 2019 | -645,156 | Reduce 58.47% | 458,266 | $56.45 |
| Q3 2019 | +261,841 | Add 31.11% | 1.1 M | $53.31 |
| Q2 2019 | +742,064 | Add 745.67% | 841,581 | $57.60 |
| Q1 2019 | +21,257 | Add 27.16% | 99,517 | $49.31 |
| Q4 2018 | +64,687 | Add 476.59% | 78,260 | $37.21 |
| Q3 2018 | -42,890 | Reduce 75.96% | 13,573 | $37.72 |
| Q2 2018 | +20,318 | Add 56.21% | 56,463 | $43.76 |
| Q1 2018 | +26,165 | Add 262.17% | 36,145 | $50.30 |
| Q4 2017 | -8,260 | Reduce 45.29% | 9,980 | $65.83 |
| Q3 2017 | -3,873 | Reduce 17.51% | 18,240 | $59.81 |
| Q2 2017 | -2,997 | Reduce 11.94% | 22,113 | $64.85 |
| Q1 2017 | -32,622 | Reduce 56.51% | 25,110 | $62.45 |
| Q4 2016 | -290,493 | Reduce 83.42% | 57,732 | $57.73 |
| Q3 2016 | -22,639 | Reduce 6.10% | 348,225 | $59.43 |
| Q2 2016 | -119,365 | Reduce 24.35% | 370,864 | $62.04 |
| Q1 2016 | +490,229 | New Buy | 490,229 | $61.63 |
Cliff Asness's DENTSPLY SIRONA Investment FAQs
Cliff Asness first purchased DENTSPLY SIRONA Inc. (XRAY) in Q1 2016, acquiring 490,229 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held DENTSPLY SIRONA Inc. (XRAY) for 41 quarters since Q1 2016.
Cliff Asness's largest addition to DENTSPLY SIRONA Inc. (XRAY) was in Q2 2025, adding 13,316,771 shares worth $211.47 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 3,965,223 shares of DENTSPLY SIRONA Inc. (XRAY), valued at approximately $45.12 M.
As of the Q1 2026 filing, DENTSPLY SIRONA Inc. (XRAY) represents approximately 0.02% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in DENTSPLY SIRONA Inc. (XRAY) was 13,316,771 shares, as reported at the end of Q2 2025.